the ova1 test improves the preoperative assessment of ovarian tumors frederick ueland, chris...
TRANSCRIPT
![Page 1: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/1.jpg)
The OVA1 Test Improves the Preoperative Assessment of
Ovarian Tumors
Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona Podzielinski, Lori Sokoll, Alan Smith, Joseph Santoso, John R. van Nagell Jr., Zhen Zhang.
![Page 2: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/2.jpg)
NIH Consensus Statement1994
“Women with ovarian masses who have been identified preoperatively as having a significant risk of ovarian cancer should be
given the option of having their surgery performed by a gynecologic oncologist”
![Page 3: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/3.jpg)
The OVA1 Test• Biomarker panel
– CA125, transthyretin (prealbumin), apolipoprotein A1beta 2 microglobulin, transferrin
• OvaCalc software algorithm• OVA1 risk index, range 0-10
Premenopausal Postmenopausal
Low Risk < 5.0 < 4.4
High Risk ≥ 5.0 ≥ 4.4
![Page 4: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/4.jpg)
Objectives
Evaluate the performance of the OVA1 test alone, and in conjunction with current clinical parameters, in estimating the risk of malignancy in women scheduled for surgery with an ovarian mass.
![Page 5: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/5.jpg)
Eligibility
• Female subjects age 18 years or older• Agreeable to phlebotomy• Documented ovarian tumor on imaging• Planned surgical intervention within 3 months of
imaging• Signed informed consent
![Page 6: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/6.jpg)
Methods• 27 primary care and specialty sites throughout U.S.• Preoperative evaluation
– imaging to confirm ovarian tumor– serum collection for CA125– physician assessment (cancer? “yes or no”)
• Centralized assay at Quest Diagnostics• Validation assays
– Johns Hopkins– Specialty Laboratories
• Independent data analysis– Applied Clinical Intelligence
![Page 7: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/7.jpg)
Study Population All Subjects
Non-GO Physicians
GO Physicians
Patients 516 269 247Mean age, yr (SD) 52 (14) 50 (14) 55 (14)Median age, yr 52 48 54Range (min, max) 18 to 92 19 to 90 18 to 92
Menopausal Status, n (%)Pre 235 (46%) 144 (54%) 91 (37%)Post 281 (54%) 125 (46%) 156 (63%)
Pathology Diagnosis, n (%)Benign ovarian condition 355 (69%) 197 (73%) 158 (64%)Epithelial ovarian cancer (EOC) 96 (19%) 45 (17%) 51 (21%)Other primary ovarian malignancy 9 (2%) 5 (2%) 4 (2%)Low malignant potential (borderline) 28 (5%) 12 (4%) 16 (6%)
Non-primary ovarian malignancy with involvement of the ovaries
18 (4%) 5 (2%) 13 (5%)
Non-primary ovarian malignancies with no involvement of ovaries
10 (2%) 5 (2%) 5 (2%)
![Page 8: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/8.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Tru
e p
osi
tive
rate
(S
en
siti
vit
y)
False positive rate (1-Specificity)
Premenopausal, AUC= 0.80 (95% CI: 0.73-0.88)Postmenopausal, AUC=0.82 (95% CI: 0.77-0.87)
OVA1 Test Alone
Receiving-operator-characteristic Curve
Sensitivity 92%
Specificity 43%
PPV 42%
NPV 93%
![Page 9: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/9.jpg)
Premenopausal Postmenopausal
PerformancePreoperativ
e assessment
Preoperative assessment plus OVA1
Preoperative
assessment
Preoperative assessment plus OVA1
Sensitivity, % 60 89 81 98
95% CI 46 to 73 76 to 95 73 to 87 94 to 100
Specificity, % 83 40 74 28
95% CI 77 to 88 34 to 48 67 to 81 22 to 35
PPV, % 46 26 69 49
95% CI 34 to 58 20 to 34 61 to 76 43 to 55
NPV, % 90 94 85 96
95% CI 84 to 93 86 to 97 78 to 90 86 to 99
Negative Likelihood Ratio
0.48 0.27 0.25 0.06
95% CI 0.33 to 0.69 0.12 to 0.64 0.17 to 0.37 0.02 to 0.25
Prevalence 19% (45/235) 41% (116/281)
![Page 10: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/10.jpg)
non-GO physicians GO physicians
PerformancePreoperativ
e assessment
Preoperative
assessment plus OVA1
Preoperative
assessment
Preoperative assessment plus OVA1
Sensitivity, % 72 92 78 99
95% CI 61 to 81 83 to 96 68 to 85 94 to 100
Specificity, % 83 42 75 26
95% CI 77 to 87 35 to 49 67 to 81 20 to 33
PPV, % 60 36 63 43
95% CI 50 to 70 30 to 44 54 to 72 36 to 50
NPV, % 89 93 86 9895% CI 84 to 93 86 to 97 79 to 90 88 to 100
Negative Likelihood Ratio
0.34 0.20 0.30 0.04
95% CI 0.23 to 0.49 0.09 to 0.44 0.20 to 0.45 0.01 to 0.31
Prevalence 27% (72/269) 36% (89/247)
![Page 11: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/11.jpg)
OVA1 Sensitivity
Tumor subtype Cancer stage
Stage Sensitivity
I 90%
II 100%
III 100%
IV 100%
Epithelial OC 99%
Non EOC 78%
LMP 75%
Metastases 94%
![Page 12: The OVA1 Test Improves the Preoperative Assessment of Ovarian Tumors Frederick Ueland, Chris Desimone, Leigh Seamon, Rachel Ware, Scott Goodrich, Iwona](https://reader036.vdocuments.site/reader036/viewer/2022070400/56649edb5503460f94beaf41/html5/thumbnails/12.jpg)
Conclusions
1. The OVA1 test successfully classifies patients into high or low probability of malignancy.
2. OVA1 has high sensitivity in premenopausal women and all stages of epithelial ovarian cancers. These results are independent of physician specialty.
3. When combined with other clinical information, the OVA1 test can help determine the risk of malignancy for an ovarian tumor before surgery, and facilitate decisions about referral to a gynecologic oncologist.